3950-10-5

Basic information

• Product Name: 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester
• Synonyms: 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester;1,6-Dihydro-4-hydroxy-2-methyl-6-oxo-3-pyridinecarboxylic acid ethyl ester;ethyl 4-hydroxy-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 3950-10-5
• Molecular Formula: C₉H₁₁NO₄
• Molecular Weight: 197.19
• Mol File: 3950-10-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 228-229 °C
• Boiling Point: 343.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.308±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester(3950-10-5)
• EPA Substance Registry System: 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester(3950-10-5)

Safety Data

• Hazardous Substances Data: 3950-10-5(Hazardous Substances Data)

Usage

General Description

1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester, also known as ethyl 2-methyl-4-oxo-6-(pyridin-2-yl)-1,4-dihydropyridine-3-carboxylate, is a chemical compound with potential medicinal properties. It is an ethyl ester derivative of nicotinic acid, also known as niacin or vitamin B3, and is used in the synthesis of pharmaceuticals. 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester has been investigated for its potential as an anti-inflammatory agent and for its effects on the cardiovascular system. It is also being studied for its potential as a treatment for neurodegenerative disorders. More research is needed to fully understand the potential uses and mechanisms of action of this compound in medicinal and pharmaceutical applications.

Upstream product

• 15781-70-1 malonic acid bis-(2,4,6-trichloro-phenyl) ester 
• 626-34-6 ethyl aminocrotonate 
• 626-34-6 ethyl 3-aminobut-2-enoate 

Downstream Products

• 59225-86-4 4,7-dimethyl-6H-pyrano[3,2-c]pyridine-2,5-dione 
• 686279-09-4 ethyl 4,6-dichloro-2-methylpyridine-3-carboxylate 
• 1390657-41-6 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-42-7 tert-butyl 4-(4-((2-((2,6-dichlorophenyl)amino)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-45-0 tert-butyl 4-(4-((2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390657-72-3 tert-butyl 4-(4-((2-(2-chlorophenoxy)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-09-3 2-(2-chlorophenoxy)-4-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390657-77-8 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxybenzyl)piperazine-1-carboxylate 
• 1390657-78-9 tert-butyl 4-(4-((2-(2-chlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxybenzyl)piperazine-1-carboxylate 
• 1390656-12-8 2-(2-chlorobenzyl)-4-{[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390657-79-0 2-chloro-4-((2-methoxy-4-(morpholinomethyl)phenyl)amino)pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390656-14-0 2-(2-chlorobenzyl)-4-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]amino}pyrido[2,3-d]pyridazin-5-ol 
• 1390657-97-2 tert-butyl 4-(4-((2-chloro-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 
• 1390657-98-3 tert-butyl 4-(4-((2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 

Relevant articles and documents

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-iodopyridin-2(1H)-one type anti-HIV agents

A series of C-5 methyl substituted 4-arylthio- and 4-aryloxy-3-iodopyridin- 2(1H)-ones has been synthesized as new pyridinone analogues for their evaluation as anti-HIV inhibitors. The optimization at the 5-position was developed through an efficient use of the key intermediates 5-ethoxycarbonyl- and 5-cyano-pyridin-2(1H)-ones (14 and 15). Biological studies revealed that several compounds show potent HIV-1 reverse transcriptase inhibitory properties, for example, compounds 93 and 99 are active at 0.6-50 nM against wild type HIV-1 and a panel of major simple/double HIV mutant strains.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.